UK Medical Cannabis Law — What Patients Need to Know

Understanding the legal framework around medical cannabis in the UK is essential for any patient considering this treatment route. While cannabis remains a Class B controlled substance under the Misuse of Drugs Act 1971, significant regulatory changes since 2018 have made it legally accessible for patients with a valid prescription from a registered specialist.

Schedule 2 Rescheduling and What It Means for Patients

In November 2018, the UK government rescheduled cannabis-based products for medicinal use from Schedule 1 to Schedule 2 of the Misuse of Drugs Regulations 2001. This was a landmark change: Schedule 1 drugs had no recognised medical use and could not be prescribed at all. Schedule 2 permits possession, supply and administration for medical purposes under strict conditions.

The rescheduling was triggered largely by high-profile cases — most notably that of Alfie Dingley and Billy Caldwell, two children with severe epilepsy whose parents campaigned publicly for access to cannabis-based medicines. Following a review by the Chief Medical Adviser, specialist doctors were given the authority to prescribe cannabis-based medicines (CBPMs) from 1 November 2018.

Crucially, only specialists registered with the General Medical Council (GMC) can issue these prescriptions. General practitioners cannot currently prescribe CBPMs under NHS guidelines, although they may continue prescriptions initiated by a specialist in some circumstances. The MHRA oversees the licensing and quality standards for all cannabis-based medicines imported or manufactured in the UK.

Prescription Requirements and MHRA Regulations

A legal CBPM prescription in the UK must be written on a Controlled Drug prescription form and comply with all standard requirements for Schedule 2 drugs: the patient's full name and address, the drug name, form, strength and total quantity, plus the prescriber's signature and GMC number. Prescriptions for Schedule 2 substances are valid for 28 days from the date of signing.

The MHRA distinguishes between licensed products and unlicensed specials. The only currently licensed cannabis-based medicine in the UK is Sativex (nabiximols), licensed for spasticity in multiple sclerosis. Epidyolex (cannabidiol) holds a licence for certain forms of childhood epilepsy. The vast majority of CBPMs prescribed through private clinics are unlicensed specials, meaning they are made by MHRA-registered manufacturers but do not hold a full product licence. This is legal under the Human Medicines Regulations 2012 provided a specialist prescriber deems them necessary for an individual patient.

Find UK licensed clinics that operate within this legal framework and can connect you with a GMC-registered specialist.

Travelling with Medical Cannabis and Legal Boundaries

One of the most common questions patients ask is whether they can travel with their medication. The answer is more complicated than many expect.

Within the UK: Patients may legally possess their prescribed cannabis-based medicine anywhere in England, Scotland, Wales and Northern Ireland, provided they carry the original dispensary packaging and, ideally, a letter from their prescribing clinician. Police have no power to seize lawfully prescribed CBPMs.

International travel: This is where significant risk arises. Cannabis remains illegal in most countries regardless of UK prescription status. Even within the EU, a UK prescription does not grant permission to possess cannabis. The Home Office can issue a personal import/export licence for Schedule 2 drugs, but these are processed individually for each trip and specific destination, and are not guaranteed. Patients are strongly advised to seek legal advice before travelling abroad with any CBPM.

For a full breakdown of qualifying conditions under current UK guidelines, or to review products available on prescription, you can compare prices across licensed pharmacies.

NHS vs Private Prescribing and Enforcement in Practice

Despite the legal framework allowing CBPM prescribing since 2018, NHS access remains extremely limited in practice. NHS England guidance currently supports prescribing only for intractable epilepsy in children, nausea and vomiting from chemotherapy, and spasticity in MS. For the vast majority of conditions — including chronic pain, anxiety, PTSD and insomnia — patients must access CBPMs through the private sector.

The disparity between what is technically legal and what is practically available on the NHS has driven the growth of private clinics. Alternaleaf, Mamedica, Releaf, Lyphe and Curaleaf operate entirely within the private sector, charging consultation and prescription fees that patients fund out of pocket. Some patients attempt to obtain NHS continuation prescriptions after a private specialist initiates treatment, but GPs are not obligated to provide these and many decline due to unfamiliarity with CBPM prescribing.

From an enforcement perspective, patients carrying their prescribed CBPMs in the original dispensary packaging with a clinician letter face very low practical risk of police interference. The Crown Prosecution Service has issued guidance that prosecution is not in the public interest where a patient can demonstrate lawful medical possession. However, the burden of proving lawful possession rests with the patient — carrying original dispensary labels and a prescriber letter is strongly advised at all times. If you are stopped by police, remain calm and present your prescription documentation clearly; officers can verify registered GMC prescribers online, and lawfully prescribed patients have never been prosecuted in the UK since the 2018 rescheduling.